Atopic dermatitis (AD) is a chronic, inflammatory, pruritic form of dermatosis with
heterogeneous manifestations that can substantially affect patients' quality of life. AD has a …

Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex
pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains …

Background Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13,
prevents the formation of the interleukin-4Rα–interleukin-13Rα1 heterodimer receptor …

The evidence‐and consensus‐based guideline on atopic eczema was developed in
accordance with the EuroGuiDerm Guideline and Consensus Statement Development …

Background Current systemic treatments for children younger than 6 years with moderate-to-
severe atopic dermatitis that is uncontrolled with topical therapies might have suboptimal …

Myeloid cells are known to suppress antitumour immunity. However, the molecular drivers of
immunosuppressive myeloid cell states are not well defined. Here we used single-cell RNA …

Importance Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease with an
unmet need for treatments that provide rapid and high levels of skin clearance and itch …

Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a
spectrum of burdensome dermatologic conditions. The US Food and Drug Administration …

Toll-like receptor–driven and interleukin-1 (IL-1) receptor–driven inflammation mediated by
IL-1 receptor–associated kinase 4 (IRAK4) is involved in the pathophysiology of hidradenitis …

Background For people with atopic dermatitis (AD) refractory to topical therapies, treatment
with phototherapy and systemic therapies can be considered. Multiple biologic therapies …